No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
H.C. Wainwright Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
NextCure Analyst Ratings
H.C. Wainwright Maintains NextCure(NXTC.US) With Buy Rating, Cuts Target Price to $3